{"id":6113,"date":"2024-12-13T09:30:00","date_gmt":"2024-12-13T08:30:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/staybles-vd-andreas-gerward-presenterade-vid-financial-stockholm-den-11-december-2024\/"},"modified":"2024-12-13T09:30:00","modified_gmt":"2024-12-13T08:30:00","slug":"staybles-vd-andreas-gerward-presenterade-vid-financial-stockholm-den-11-december-2024","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/staybles-vd-andreas-gerward-presenterade-vid-financial-stockholm-den-11-december-2024\/","title":{"rendered":"Staybles VD, Andreas Gerward, presenterade vid Financial Stockholm den 11 december 2024"},"content":{"rendered":"<p style=\"margin-bottom:0pt;margin-top:12px\"><a href=\"https:\/\/www.youtube.com\/watch?v=41H9eQ57mlc\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>https:\/\/www.youtube.com\/watch?v=41H9eQ57mlc<\/u><\/span><\/a><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>&nbsp;<\/strong><\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">F\u00f6r mer information<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">E-post: andreas.gerward@stayble.se <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Telefon: +46 730 808<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">397<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">Om Stayble Therapeutics AB<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot kroniskt diskbr\u00e5ck (LDH). Staybles vision \u00e4r att kunna erbjuda patienter en enkel och effektiv behandling som angriper den underliggande orsaken patientens kroniska sm\u00e4rta och ger varaktig sm\u00e4rtlindring och \u00f6kad fysisk funktion. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat och \u00e4r en singelinjektion som ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4ver minimal rehabilitering. Efter \u00f6vertygande data fr\u00e5n tidigare prekliniska och kliniska studier (fas 1b och 2b) inom degenerativ disksjukdom, vilka visar p\u00e5 en volymminskning av diskarna har Bolaget framg\u00e5ngsrikt genomf\u00f6rt en fas 1b-studien f\u00f6r behandling av diskbr\u00e5ck.<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Staybles Therapeutics ABs (\u201dStayble\u201d eller \u201dBolaget\u201d) VD, Andreas Gerward, presenterade Bolaget, resultat fr\u00e5n fas 1b samt v\u00e4gen fram\u00e5t vid Financial Stockholms arrangemang \u201dInvestera som Proffsen\u201d den 11 december 2024. Se den inspelade presentationen nedan:<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/6113"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=6113"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/6113\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=6113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}